|
DE60122286T2
(de)
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
ES2393733T3
(es)
|
2001-03-07 |
2012-12-27 |
Merck Patent Gmbh |
Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
EP1383785B1
(en)
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
CN100390282C
(zh)
|
2001-12-04 |
2008-05-28 |
默克专利有限公司 |
具有调节的选择性的il-2融合蛋白
|
|
ES2442615T5
(es)
|
2002-07-18 |
2023-03-16 |
Merus Nv |
Producción recombinante de mezclas de anticuerpos
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
RU2369616C2
(ru)
|
2003-12-30 |
2009-10-10 |
Мерк Патент Гмбх |
Слитые белки il-7
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
NZ576404A
(en)
|
2006-09-29 |
2012-02-24 |
Oncomed Pharm Inc |
Compositions and methods for diagnosing and treating cancer involving dll4
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
AU2015202560B2
(en)
*
|
2008-01-07 |
2017-06-15 |
Amgen Inc. |
Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects
|
|
WO2009089004A1
(en)
*
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
WO2009130031A1
(en)
*
|
2008-04-25 |
2009-10-29 |
Merck Patent Gmbh, |
Artificial protein scaffolds
|
|
WO2009134776A2
(en)
|
2008-04-29 |
2009-11-05 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR101431318B1
(ko)
*
|
2009-04-02 |
2014-08-20 |
로슈 글리카트 아게 |
전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
SG175233A1
(en)
|
2009-04-22 |
2011-11-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
US9067986B2
(en)
*
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9308258B2
(en)
|
2009-07-08 |
2016-04-12 |
Amgen Inc. |
Stable and aggregation free antibody FC molecules through CH3 domain interface engineering
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
DK2488204T3
(en)
|
2009-10-16 |
2016-06-06 |
Oncomed Pharm Inc |
Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
RS65965B1
(sr)
|
2010-04-20 |
2024-10-31 |
Genmab As |
Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
PL2635607T3
(pl)
*
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
WO2012064792A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
KR20240025059A
(ko)
|
2010-11-30 |
2024-02-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
BR112013020338A2
(pt)
|
2011-02-28 |
2016-10-18 |
Hoffmann La Roche |
proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
|
|
KR101638224B1
(ko)
|
2011-02-28 |
2016-07-08 |
에프. 호프만-라 로슈 아게 |
항원 결합 단백질
|
|
EA201791693A1
(ru)
*
|
2011-03-25 |
2018-05-31 |
Гленмарк Фармасьютикалс С.А. |
Гетеродимерные иммуноглобулины
|
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー／エス |
Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
TWI583699B
(zh)
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SG11201401422VA
(en)
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
ES2732712T3
(es)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
|
EP2773671B1
(en)
|
2011-11-04 |
2021-09-15 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
AU2012336069A1
(en)
|
2011-11-07 |
2014-05-22 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
|
SI2794905T1
(sl)
|
2011-12-20 |
2020-08-31 |
Medimmune, Llc |
Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
|
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
KR102545770B1
(ko)
|
2012-04-20 |
2023-06-21 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
EP3401337A1
(en)
|
2012-09-25 |
2018-11-14 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
TR201815768T4
(tr)
|
2012-09-27 |
2018-11-21 |
Merus Nv |
T hücre bağlayıcılar olarak bispesifik IgG antikorları.
|
|
US9771573B2
(en)
|
2012-10-03 |
2017-09-26 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
|
EP2912058A1
(en)
|
2012-10-23 |
2015-09-02 |
The Board of Regents of The University of Texas System |
Antibodies with engineered igg fc domains
|
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
|
|
WO2014079000A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
BR112015012385A2
(pt)
|
2012-11-28 |
2019-08-27 |
Zymeworks Inc |
constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR20240123420A
(ko)
|
2013-01-10 |
2024-08-13 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
CN110981964B
(zh)
|
2013-01-14 |
2023-09-15 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
WO2014126884A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
US10183967B2
(en)
|
2013-02-12 |
2019-01-22 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
KR20180023035A
(ko)
|
2013-02-26 |
2018-03-06 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
CA2906526C
(en)
|
2013-03-15 |
2022-12-06 |
Ellen Chi |
Interferon alpha and omega antibody antagonists
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
PL2976361T3
(pl)
|
2013-03-18 |
2018-12-31 |
Biocerox Products B.V. |
Humanizowane przeciwciała anty-CD134 (OX40) i ich zastosowania
|
|
PE20151807A1
(es)
|
2013-04-29 |
2015-12-02 |
Hoffmann La Roche |
Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
|
|
PL2992010T3
(pl)
|
2013-04-29 |
2021-08-23 |
F.Hoffmann-La Roche Ag |
Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
|
|
KR20160003803A
(ko)
|
2013-04-29 |
2016-01-11 |
에프. 호프만-라 로슈 아게 |
FcRn 결합이 제거된 항-IGF-1R 항체 및 혈관 눈 질환의 치료에 있어서 이의 용도
|
|
HUE048722T2
(hu)
|
2013-07-05 |
2020-08-28 |
Genmab As |
Humanizált vagy kiméra CD3 ellenanyagok
|
|
MX2016003616A
(es)
|
2013-09-27 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir heteromultimeros de polipeptidos.
|
|
CN105612182B
(zh)
|
2013-10-11 |
2019-12-10 |
豪夫迈·罗氏有限公司 |
多特异性结构域交换共有可变轻链抗体
|
|
LT3065774T
(lt)
|
2013-11-06 |
2021-09-10 |
Janssen Biotech, Inc. |
Anti-ccl17 antikūnai
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
CR20160314A
(es)
|
2013-12-17 |
2016-08-29 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
SG11201605044RA
(en)
|
2013-12-20 |
2016-07-28 |
Hoffmann La Roche |
HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
|
|
RU2693438C2
(ru)
|
2014-01-03 |
2019-07-02 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
|
|
KR20160105799A
(ko)
|
2014-01-06 |
2016-09-07 |
에프. 호프만-라 로슈 아게 |
1가 혈액 뇌 장벽 셔틀 모듈
|
|
EP3094647A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CA2941077A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus N.V. |
Antibody that binds erbb-2 and erbb-3
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
WO2015130172A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibodies that bind egfr and erbb3
|
|
MY187246A
(en)
|
2014-03-14 |
2021-09-14 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
WO2015149077A1
(en)
|
2014-03-28 |
2015-10-01 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
JP6666262B2
(ja)
|
2014-04-02 |
2020-03-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体の軽鎖誤対合を検出するための方法
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
DK3107938T3
(da)
|
2014-05-28 |
2022-07-11 |
Zymeworks Inc |
Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
BR112016029935A2
(pt)
|
2014-06-26 |
2017-10-31 |
Hoffmann La Roche |
?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
|
|
BR112016030740A2
(pt)
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
diacorpos heterodiméricos biespecíficos e seus usos
|
|
NZ728019A
(en)
|
2014-07-11 |
2022-09-30 |
Genmab As |
Antibodies binding axl
|
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG11201700476VA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
KR102411972B1
(ko)
|
2014-08-04 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
CN107108744B
(zh)
|
2014-08-19 |
2020-09-25 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
|
AU2015315396B2
(en)
|
2014-09-09 |
2020-10-08 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
US11952421B2
(en)
|
2014-10-09 |
2024-04-09 |
Bristol-Myers Squibb Company |
Bispecific antibodies against CD3EPSILON and ROR1
|
|
MA40035A
(fr)
|
2014-10-14 |
2016-04-21 |
Dana Farber Cancer Inst Inc |
Molécules d'anticorps de pd-l1 et leurs utilisations
|
|
EP3212233B1
(en)
|
2014-10-31 |
2020-06-24 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
RU2713131C1
(ru)
|
2014-11-06 |
2020-02-03 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
CN107207609B
(zh)
|
2014-11-20 |
2022-07-19 |
豪夫迈·罗氏有限公司 |
共同轻链和使用方法
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
WO2016087650A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Merck Patent Gmbh |
Domain-exchanged antibody
|
|
WO2016097300A1
(en)
|
2014-12-19 |
2016-06-23 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
JP6724023B2
(ja)
|
2015-02-09 |
2020-07-15 |
リサーチ ディベロップメント ファウンデーション |
改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
BR112017021500A2
(pt)
|
2015-04-08 |
2018-09-25 |
Novartis Ag |
terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016187546A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
|
|
CN104833797B
(zh)
*
|
2015-06-04 |
2017-02-01 |
武汉友芝友生物制药有限公司 |
检测双特异性抗体msbody的elisa方法及应用
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
|
CN107849132B
(zh)
|
2015-06-16 |
2022-03-08 |
豪夫迈·罗氏有限公司 |
人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
|
|
CR20170587A
(es)
|
2015-06-22 |
2018-04-03 |
Janssen Biotech Inc |
Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
KR20240150522A
(ko)
|
2015-06-24 |
2024-10-15 |
얀센 바이오테크 인코포레이티드 |
Cd38과 특이적으로 결합하는 항체에 의한 고형 종양의 면역 조절 및 치료
|
|
EP3319996B1
(en)
|
2015-07-09 |
2024-01-03 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
|
LT3115376T
(lt)
|
2015-07-10 |
2018-11-12 |
Merus N.V. |
Antikūnai, kurie jungiasi su žmogaus cd3
|
|
WO2017009442A1
(en)
|
2015-07-15 |
2017-01-19 |
Genmab A/S |
Humanized or chimeric cd3 antibodies
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
EP4450088A2
(en)
|
2015-07-30 |
2024-10-23 |
MacroGenics, Inc. |
Pd-1-binding molecules and methods of use thereof
|
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
|
JP6967003B2
(ja)
|
2015-09-23 |
2021-11-17 |
メレオ バイオファーマ ５ インコーポレイテッド |
がんの処置のための方法および組成物
|
|
JP2018529351A
(ja)
|
2015-09-30 |
2018-10-11 |
ヤンセン バイオテツク，インコーポレーテツド |
ヒトｃｄ４０に特異的に結合するアンタゴニスト抗体及び使用方法
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
MA43025A
(fr)
|
2015-10-02 |
2021-05-26 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
MX2018003630A
(es)
|
2015-10-02 |
2018-08-01 |
F Hoffmann La Roche Ag |
Anticuerpos biespecificos para pd1 y tim3.
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
|
US11174315B2
(en)
|
2015-10-08 |
2021-11-16 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
|
MX2018004285A
(es)
|
2015-10-08 |
2018-11-09 |
Zymeworks Inc |
Construcciones polipeptidicas de union al antigeno que comprenden cadenas ligeras kappa y lambda y usos de estas.
|
|
KR20180100305A
(ko)
|
2015-10-23 |
2018-09-10 |
메뤼스 엔.페. |
암 성장을 억제하는 결합 분자
|
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
|
CN108472369A
(zh)
|
2015-11-03 |
2018-08-31 |
詹森生物科技公司 |
抗cd38抗体的皮下制剂及其用途
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
CA3003759A1
(en)
|
2015-11-03 |
2017-05-11 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
|
UA125611C2
(uk)
|
2015-12-14 |
2022-05-04 |
Макродженікс, Інк. |
Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
|
EP3389713A2
(en)
|
2015-12-17 |
2018-10-24 |
Novartis AG |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
TW202342540A
(zh)
|
2016-03-14 |
2023-11-01 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
MX2018011542A
(es)
|
2016-03-22 |
2019-02-07 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas.
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
JP7497955B6
(ja)
|
2016-04-15 |
2024-07-01 |
ノバルティス アーゲー |
選択的タンパク質発現のための組成物および方法
|
|
US10961311B2
(en)
|
2016-04-15 |
2021-03-30 |
Macrogenics, Inc. |
B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
BR112018071283A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
|
|
BR112018071285A2
(pt)
|
2016-04-20 |
2019-02-12 |
Regeneron Pharma |
célula, conjunto de vetores, vetor, sistema, e, método
|
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
DK3478830T3
(da)
|
2016-07-01 |
2024-05-21 |
Resolve Therapeutics Llc |
Optimerede binucleasefusioner og metoder
|
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
|
CN109641959B
(zh)
|
2016-07-14 |
2023-08-22 |
健玛保 |
针对cd40和cd137的多特异性抗体
|
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
CN110214150A
(zh)
|
2016-07-28 |
2019-09-06 |
诺华股份有限公司 |
嵌合抗原受体和pd-1抑制剂的组合疗法
|
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
MX2019001651A
(es)
|
2016-08-10 |
2019-09-04 |
Univ Ajou Ind Academic Coop Found |
Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma.
|
|
MA45941A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
|
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PL3512882T3
(pl)
*
|
2016-09-14 |
2022-01-10 |
Merck Patent Gmbh |
Przeciwciała anty-c-met i ich koniugaty przeciwciał z lekami do efektywnej inhibicji nowotworów
|
|
US10738120B2
(en)
|
2016-09-20 |
2020-08-11 |
Merck Patent Gmbh |
Diagnostic anti-PD-L1 antibody and use thereof
|
|
US10882918B2
(en)
|
2016-09-30 |
2021-01-05 |
Hoffmann-La Roche Inc. |
Bispecific T cell activating antigen binding molecules
|
|
EP3519820B1
(en)
|
2016-09-30 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
|
MX2019003886A
(es)
|
2016-10-07 |
2019-08-05 |
Novartis Ag |
Receptores de antigenos quimericos para el tratamiento del cancer.
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
SG11201903693QA
(en)
|
2016-11-01 |
2019-05-30 |
Genmab Bv |
Polypeptide variants and uses thereof
|
|
JP2020503260A
(ja)
|
2016-11-15 |
2020-01-30 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018095932A1
(en)
|
2016-11-22 |
2018-05-31 |
Merck Patent Gmbh |
Monoclonal antibody directed to fgfr1
|
|
KR102630036B1
(ko)
|
2016-12-23 |
2024-01-29 |
마크로제닉스, 인크. |
Adam9-결합 분자, 및 이것의 사용 방법
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
JP7123063B2
(ja)
|
2017-02-02 |
2022-08-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ドメインの好ましい対形成
|
|
EP3580233A1
(en)
|
2017-02-10 |
2019-12-18 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
EP3586872A4
(en)
|
2017-02-24 |
2020-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
|
|
JP7116736B2
(ja)
|
2017-03-02 |
2022-08-10 |
ノバルティス アーゲー |
操作されたヘテロ二量体タンパク質
|
|
MA49823A
(fr)
|
2017-03-09 |
2021-04-21 |
Genmab As |
Anticorps dirigés contre pd-l1
|
|
WO2018162517A1
(en)
|
2017-03-10 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Method for producing multispecific antibodies
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
CN110650752A
(zh)
|
2017-03-31 |
2020-01-03 |
美勒斯公司 |
用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｓｔｅａｐ－１に結合する抗体
|
|
MX2019011858A
(es)
|
2017-04-03 |
2019-11-21 |
Oncologie Inc |
Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
|
|
CR20190435A
(es)
|
2017-04-05 |
2019-11-12 |
Hoffmann La Roche |
Anticuerpos biespecíficos de unión específica a pd1 y lag3
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
|
|
KR20200027944A
(ko)
|
2017-06-07 |
2020-03-13 |
젠맵 비. 브이 |
돌연변이된 igg 육량체에 기초한 치료 항체
|
|
BR112019027104A2
(pt)
|
2017-06-22 |
2020-08-18 |
Novartis Ag |
moléculas de anticorpo para cd73 e usos das mesmas
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
|
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
KR20200064062A
(ko)
|
2017-08-04 |
2020-06-05 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
MX2020001432A
(es)
|
2017-08-09 |
2020-03-20 |
Merus Nv |
Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
|
CA3072129A1
(en)
|
2017-08-30 |
2019-03-07 |
Ares Trading S.A. |
Method for purifying proteins
|
|
KR20200059249A
(ko)
|
2017-09-21 |
2020-05-28 |
유엠씨 우트레크트 홀딩 비.브이. |
신경아세포종의 치료를 위한 항-gd2 항체
|
|
JP7237945B2
(ja)
|
2017-09-21 |
2023-03-13 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｆｇｆ－１８部分を含む融合タンパク質
|
|
KR20200067197A
(ko)
|
2017-10-20 |
2020-06-11 |
에프. 호프만-라 로슈 아게 |
단일특이적 항체로부터 다중특이적 항체의 생성 방법
|
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
AU2018358904A1
(en)
|
2017-11-01 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
TriFab-contorsbody
|
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
|
TWI829658B
(zh)
|
2017-11-01 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性2+1康特斯體(Contorsbody)
|
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃｏｍｐボディ−多価標的結合物質
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
CN111465618A
(zh)
|
2017-12-12 |
2020-07-28 |
宏观基因有限公司 |
双特异性cd16-结合分子及其在疾病治疗中的用途
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
SG11202005632SA
(en)
|
2017-12-21 |
2020-07-29 |
Hoffmann La Roche |
Antibodies binding to hla-a2/wt1
|
|
EP3728327A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
US11067584B2
(en)
|
2018-01-12 |
2021-07-20 |
Genzyme Corporation |
Methods for the quantitation of polypeptides
|
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
MX2020007527A
(es)
|
2018-02-06 |
2020-09-09 |
Hoffmann La Roche |
Tratamiento de enfermedades oftalmologicas.
|
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP7466442B2
(ja)
|
2018-02-14 |
2024-04-12 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
BR112020016485A2
(pt)
|
2018-02-15 |
2020-12-15 |
Macrogenics, Inc. |
Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença
|
|
MX2020009379A
(es)
|
2018-03-12 |
2020-10-14 |
Genmab As |
Anticuerpos.
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
CA3098486A1
(en)
|
2018-05-03 |
2019-11-07 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
US12012461B2
(en)
|
2018-05-16 |
2024-06-18 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
|
|
EP4257611A3
(en)
|
2018-05-18 |
2024-03-06 |
Glycotope GmbH |
Anti-muc1 antibody
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
BR112020023872A2
(pt)
|
2018-05-24 |
2021-02-17 |
Janssen Biotech, Inc. |
agentes de ligação de psma e seus usos
|
|
EP3802608A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Anti-cd3 antibodies and uses thereof
|
|
CN112703203A
(zh)
|
2018-05-24 |
2021-04-23 |
詹森生物科技公司 |
单特异性和多特异性抗-tmeff2抗体及其用途
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
SG11202011830SA
(en)
|
2018-06-13 |
2020-12-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
SG11202012712YA
(en)
|
2018-06-19 |
2021-01-28 |
Atarga Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
PE20211858A1
(es)
|
2018-07-13 |
2021-09-21 |
Genmab As |
Variantes de anticuerpos anti-cd38 y sus usos
|
|
JP7534281B2
(ja)
|
2018-07-13 |
2024-08-14 |
ジェンマブ エー／エス |
Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
CA3110039A1
(en)
|
2018-08-29 |
2020-03-05 |
Merck Biodevelopment S.A.S. |
New purification method
|
|
WO2020045545A1
(ja)
|
2018-08-29 |
2020-03-05 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
CA3155293A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
SG11202103100SA
(en)
|
2018-10-04 |
2021-04-29 |
Genmab Holding B V |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
US11377477B2
(en)
|
2018-10-12 |
2022-07-05 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
|
|
BR112021007175A2
(pt)
|
2018-10-23 |
2021-08-10 |
Dragonfly Therapeutics, Inc. |
proteínas fundidas a fc heterodimérico
|
|
AU2019370601B2
(en)
|
2018-10-29 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
CN113272317A
(zh)
|
2018-11-02 |
2021-08-17 |
华盛顿大学 |
正交蛋白异二聚体
|
|
US20210369842A1
(en)
|
2018-11-06 |
2021-12-02 |
Genmab A/S |
Antibody formulation
|
|
KR20210107628A
(ko)
|
2018-11-13 |
2021-09-01 |
콤파스 테라퓨틱스 엘엘씨 |
체크포인트 분자에 대한 다중특이적 결합 작제물 및 이의 용도
|
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
EP4249513A3
(en)
|
2018-12-20 |
2023-12-20 |
Novartis AG |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
CA3123177A1
(en)
|
2018-12-21 |
2020-06-25 |
Kymab Limited |
Fixaxfx bispecific antibody with common light chain
|
|
CN118271445A
(zh)
|
2018-12-21 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
BR112021012337A2
(pt)
|
2018-12-24 |
2021-09-14 |
Sanofi |
Proteínas de ligação multiespecíficas baseadas em pseudofab
|
|
JP2022515424A
(ja)
|
2018-12-24 |
2022-02-18 |
サノフイ |
突然変異ｆａｂドメインを有する多重特異性結合タンパク質
|
|
WO2020136060A1
(en)
|
2018-12-28 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
CN113329759A
(zh)
*
|
2019-01-07 |
2021-08-31 |
沙塔克实验室有限公司 |
用于调节γδT细胞的异二聚体蛋白
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
BR112021013824A2
(pt)
|
2019-01-18 |
2021-12-14 |
Janssen Biotech Inc |
Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
|
|
WO2020165833A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
EP3927746A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
CN113840842A
(zh)
|
2019-02-26 |
2021-12-24 |
詹森生物科技公司 |
利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
|
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
|
|
US20220185876A1
(en)
|
2019-03-29 |
2022-06-16 |
Atarga, Llc |
Anti fgf23 antibody
|
|
WO2020200944A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Method for generating avid-binding multispecific antibodies
|
|
EP3956022A1
(en)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
WO2020216879A1
(en)
|
2019-04-25 |
2020-10-29 |
F. Hoffmann-La Roche Ag |
Therapeutic multispecific polypeptides activated by polypeptide chain exchange
|
|
KR20220005031A
(ko)
|
2019-04-25 |
2022-01-12 |
에프. 호프만-라 로슈 아게 |
폴리펩티드 사슬 교환에 의한 항체-유래된 폴리펩티드의 산출
|
|
JP2022530034A
(ja)
|
2019-04-25 |
2022-06-27 |
エフ．ホフマン－ラ ロシュ アーゲー |
半減期が延長された活性化可能な治療用多重特異性ポリペプチド
|
|
MX2021013532A
(es)
|
2019-05-08 |
2022-02-11 |
Janssen Biotech Inc |
Materiales y metodos para modular la inmunidad mediada por celulas t.
|
|
MA55881A
(fr)
|
2019-05-09 |
2022-03-16 |
Genmab Bv |
Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer
|
|
WO2020229378A1
(en)
|
2019-05-13 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Interference-suppressed pharmacokinetic immunoassay
|
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
AU2020285636A1
(en)
*
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
WO2020254357A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
JP7450647B2
(ja)
|
2019-06-26 |
2024-03-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
EP4004057A1
(en)
|
2019-07-26 |
2022-06-01 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
WO2021018859A2
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
KR20220062494A
(ko)
|
2019-08-15 |
2022-05-17 |
얀센 바이오테크 인코포레이티드 |
개선된 단일 사슬 가변 단편을 위한 재료 및 방법
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
AU2020387709A1
(en)
|
2019-11-18 |
2022-07-07 |
Janssen Biotech, Inc. |
Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof
|
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
CN114867532A
(zh)
|
2019-12-18 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
EP4076666A1
(en)
|
2019-12-18 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/mage-a4
|
|
TW202135858A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
BR112022013553A2
(pt)
|
2020-01-16 |
2022-09-06 |
Genmab As |
Composição farmacêutica, anticorpo, e, método para tratar uma doença
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
|
|
KR20220144377A
(ko)
|
2020-01-30 |
2022-10-26 |
우모자 바이오파마 인코포레이티드 |
이중특이적 형질도입 촉진제
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP4233895A3
(en)
|
2020-03-13 |
2023-09-27 |
Janssen Biotech, Inc. |
Materials and methods for binding siglec-3/cd33
|
|
WO2021185934A1
(en)
|
2020-03-18 |
2021-09-23 |
Genmab A/S |
Antibodies binding to b7h4
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
IL296428A
(en)
|
2020-03-25 |
2022-11-01 |
Lilly Co Eli |
Multispecific binding proteins and methods for their development
|
|
EP4135848A2
(en)
|
2020-04-15 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Immunoconjugates
|
|
JP2023523401A
(ja)
|
2020-04-15 |
2023-06-05 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
JP2023524068A
(ja)
|
2020-04-30 |
2023-06-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
サイトカイン関連有害事象を治療する方法
|
|
EP4149524A1
(en)
|
2020-05-11 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
AU2021281134A1
(en)
|
2020-05-27 |
2023-02-09 |
Janssen Biotech, Inc. |
Proteins comprising CD3 antigen binding domains and uses thereof
|
|
JP2023528488A
(ja)
|
2020-06-03 |
2023-07-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｅｇｆｒおよびｍｕｃ１を標的とする二重特異性抗体－薬物抱合体およびその使用
|
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
|
CR20220629A
(es)
|
2020-06-19 |
2023-02-17 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
AR122656A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 / folr1
|
|
BR112022025574A2
(pt)
|
2020-06-19 |
2023-01-03 |
Hoffmann La Roche |
Anticorpos que se ligam a cd3, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3 e para tratar uma doença em um indivíduo, composição farmacêutica, anticorpo para uso e invenção
|
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
|
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー．ブイ． |
多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
KR20230041819A
(ko)
|
2020-07-29 |
2023-03-24 |
얀센 바이오테크 인코포레이티드 |
Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
|
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
WO2022029011A1
(en)
|
2020-08-06 |
2022-02-10 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CN116917316A
(zh)
|
2020-08-26 |
2023-10-20 |
马伦戈治疗公司 |
与NKp30结合的抗体分子及其用途
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
EP4204450A4
(en)
|
2020-08-26 |
2024-11-13 |
Marengo Therapeutics Inc |
MULTIFUNCTIONAL MOLECULES BINDING TO CALRETICULIN AND USES THEREOF
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022049220A2
(en)
|
2020-09-02 |
2022-03-10 |
Genmab A/S |
Antibody therapy
|
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
CA3192251A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
KR20230069187A
(ko)
|
2020-09-14 |
2023-05-18 |
서트로 바이오파마, 인크. |
무세포 단백질 합성 시스템을 이용한 항체의 대량 생산 방법
|
|
WO2022063877A1
(en)
|
2020-09-24 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with gene knockout
|
|
MX2023003749A
(es)
|
2020-10-02 |
2023-04-24 |
Genmab As |
Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).
|
|
WO2022081516A1
(en)
|
2020-10-13 |
2022-04-21 |
Janssen Biotech, Inc. |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
US12024559B2
(en)
|
2020-10-23 |
2024-07-02 |
Asher Biotherapeutics, Inc. |
Fusions with CD8 antigen binding molecules for modulating immune cell function
|
|
TW202233674A
(zh)
|
2020-10-28 |
2022-09-01 |
美商健生生物科技公司 |
用於調節δγ鏈介導之免疫的組成物及方法
|
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Ｆｃ変異体
|
|
WO2022100613A1
(zh)
|
2020-11-10 |
2022-05-19 |
上海齐鲁制药研究中心有限公司 |
针对密蛋白18a2和cd3的双特异性抗体及其应用
|
|
AU2021378316A1
(en)
|
2020-11-13 |
2023-06-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
MX2023007133A
(es)
|
2020-12-17 |
2023-06-27 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos.
|
|
WO2022128716A1
(en)
|
2020-12-17 |
2022-06-23 |
Merck Patent Gmbh |
Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate
|
|
CN116601175A
(zh)
|
2020-12-18 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
用于靶向疗法的前体蛋白和试剂盒
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
BR112023015097A2
(pt)
|
2021-01-28 |
2023-10-03 |
Janssen Biotech Inc |
Proteínas de ligação a psma e usos das mesmas
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
AU2022224508A1
(en)
|
2021-02-16 |
2023-10-05 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
MX2023010633A
(es)
|
2021-03-09 |
2023-11-28 |
Janssen Biotech Inc |
Tratamiento de canceres que carecen de mutaciones activadoras de egfr.
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
BR112023017887A2
(pt)
|
2021-03-12 |
2023-10-10 |
Genmab As |
Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico
|
|
UY39683A
(es)
|
2021-03-24 |
2022-09-30 |
Janssen Biotech Inc |
Anticuerpo dirigido a cd22 y cd79b
|
|
AR125212A1
(es)
|
2021-03-24 |
2023-06-28 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
|
|
JP2024514077A
(ja)
|
2021-03-31 |
2024-03-28 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｃｒに結合する多機能性分子およびその使用
|
|
IL307899A
(en)
|
2021-04-22 |
2023-12-01 |
Guangdong Fapon Biopharma Inc |
A bispecific multifunctional fusion polypeptide
|
|
KR20240005722A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
|
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
|
CN117396509A
(zh)
|
2021-05-07 |
2024-01-12 |
健玛保 |
包含结合b7h4和cd3的双特异性抗体的药物组合物
|
|
TW202306990A
(zh)
|
2021-05-12 |
2023-02-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
|
|
MX2023013307A
(es)
|
2021-05-14 |
2023-12-04 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno.
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
CA3219181A1
(en)
|
2021-05-19 |
2022-11-24 |
Yik Andy Yeung |
Il-21 polypeptides and targeted constructs
|
|
EP4355775A1
(en)
|
2021-06-18 |
2024-04-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-ccl2 antibodies
|
|
CA3223375A1
(en)
|
2021-06-21 |
2022-12-29 |
Ugur Sahin |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
MX2023015416A
(es)
|
2021-07-02 |
2024-04-30 |
Genentech Inc |
Procedimientos y composiciones para tratar el cancer.
|
|
AU2022309554A1
(en)
|
2021-07-14 |
2024-02-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
JP2024527020A
(ja)
|
2021-07-27 |
2024-07-19 |
モルフォシス・アーゲー |
抗原結合分子の組合せ
|
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
|
EP4399227A1
(en)
|
2021-09-06 |
2024-07-17 |
Genmab A/S |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
|
WO2023037333A1
(en)
|
2021-09-13 |
2023-03-16 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
TW202323277A
(zh)
|
2021-09-23 |
2023-06-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｋｌｂ抗體及用途
|
|
EP4405392A1
(en)
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
|
TW202323304A
(zh)
|
2021-09-30 |
2023-06-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｉｌ２３抗體融合蛋白及用途
|
|
WO2023057571A1
(en)
|
2021-10-08 |
2023-04-13 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
EP4416174A1
(en)
|
2021-10-14 |
2024-08-21 |
F. Hoffmann-La Roche AG |
New interleukin-7 immunoconjugates
|
|
MX2024005392A
(es)
|
2021-11-03 |
2024-08-06 |
Janssen Biotech Inc |
Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
MX2024006205A
(es)
|
2021-11-22 |
2024-08-19 |
Janssen Biotech Inc |
Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.
|
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
TW202337902A
(zh)
|
2022-02-07 |
2023-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｓｍａ和ｃｄ３的抗原結合分子及其醫藥用途
|
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
CN118510815A
(zh)
|
2022-02-11 |
2024-08-16 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
CN118660910A
(zh)
|
2022-03-14 |
2024-09-17 |
江苏恒瑞医药股份有限公司 |
特异性结合gprc5d和cd3的抗原结合分子及其医药用途
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
WO2023175064A1
(en)
|
2022-03-17 |
2023-09-21 |
Astrazeneca Ab |
Methods for purifying bispecific antibodies
|
|
IL314211A
(en)
|
2022-03-23 |
2024-09-01 |
Genentech Inc |
Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
|
|
AU2023245607A1
(en)
|
2022-03-29 |
2024-10-31 |
Ngm Biopharmaceuticals, Inc. |
Ilt3 and cd3 binding agents and methods of use thereof
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
|
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
TW202409090A
(zh)
|
2022-05-12 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到ｃｄ２７之結合劑
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
WO2024003837A1
(en)
|
2022-06-30 |
2024-01-04 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
TW202432177A
(zh)
|
2022-10-31 |
2024-08-16 |
丹麥商珍美寶股份有限公司 |
Ｃｄ３８抗體及其用途
|
|
WO2024095173A1
(en)
|
2022-11-02 |
2024-05-10 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
|
WO2024104988A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
|
WO2024153725A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|